A clinical study conducted in Dubai evaluating the effectiveness of Spravato (Esketamine), an NMDA receptor antagonist, in patients with major depressive disorder or treatment‑resistant depression who did not respond to standard therapies.
Location: Dubai, United Arab Emirates
Duration: January 1, 2026 – March 2026
Status: Ongoing